Class: Antiparkinsonian, Anticholinergic
Dosage Forms. Tablet: 0.5 mg, 1 mg, 2 mg
Common FDA Label Indication, Dosing, and Titration.
1. Extrapyramidal disease, medication-induced movement disorder: Adults, 1-4 mg po daily or bid; Children 3 y and older, 1-2 mg/kg/d
2. Parkinsonism: 1-2 mg/d po, may titrate to range 0.5-6 mg/d po
Off-Label Uses. None
MOA. Benztropine mesylate possesses anticholinergic and antihistamine effects. May inhibit reuptake and storage of dopamine.
Drug Characteristics: Benztropine
Medication Safety Issues: Benztropine
Drug Interactions: Benztropine
Adverse Reactions: Benztropine
Efficacy Monitoring Parameters. Reduction of extrapyramidal movements, rigidity, tremor, gait disturbances.
Toxicity Monitoring Parameters. Monitor for anticholinergic effects including dry mouth and constipation.
Key Patient Counseling Points. Drug may impair heat regulation. Advise patient to use caution with activities leading to an increased core temperature, such as strenuous exercise, exposure to extreme heat, or dehydration. Patient should avoid activities requiring mental alertness or coordination until drug effects are realized. Instruct patient to report sudden muscle weakness or stiffness, and signs/symptoms of tardive dyskinesia (tongue thrusting, facial grimacing/tics, random movements of extremities). Patient should not drink alcohol while taking this drug.
Clinical Pearls. Benztropine may have more adverse effects than amantadine when used for Parkinson disease.